Editorial
|
|
|
A drug company tried to exploit the conflicts of interest concept
|
|
|
New Products
|
|
|
Multiple sclerosis: just a metabolite of leflunomide
|
|
|
|
|
|
With longer follow-up: even more toxic than suspected
|
|
|
|
|
|
|
|
|
Biased evaluation, evidence of serious risks
|
|
|
Adverse Effects
|
|
|
Mostly in elderly men
|
|
|
|
|
|
Beware of large cumulative doses
|
|
|
|
|
|
Especially during long-term treatment
|
|
|
Reviews
|
|
|
Randomised trials: uncertain, at best modest, reduction in deaths from breast cancer
|
|
|
|
|
|
|
|
|
|
71 drugs more harmful than beneficial
|
|
|
|
|
|
Major implications for the efficient management of healthcare expenditure
|
|
|
|
|